Structure of Activated Thrombin-Activatable Fibrinolysis Inhibitor, a Molecular Link between Coagulation and Fibrinolysis

Molecular Cell

Volumn 31, Issue 4, 2008, Pages 598-606

  Sanglas, Laura ^a   Valnickova, Zuzana ^b   Arolas, Joan L ^c   Pallarés, Irantzu ^a   Guevara, Tibisay ^c   Solà, Maria ^c   Kristensen, Torsten ^b   Enghild, Jan J ^b   Aviles, Francesc X ^a   Gomis Rüth, F Xavier ^c  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b AARHUS UNIVERSITY   (Denmark)

^c INSTITUT DE BIOLOGIA MOLECULAR DE BARCELONA   (Spain)

Author keywords

PROTEIN

Indexed keywords

HYDROLASE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ARTICLE; BINDING SITE; BLOOD CLOTTING; CRYSTAL STRUCTURE; ENZYME STRUCTURE; FIBRINOLYSIS; POINT MUTATION; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN STABILITY;

AMINO ACID SEQUENCE; ANIMALS; BINDING SITES; BIOLOGICAL ASSAY; BLOOD COAGULATION; CARBOXYPEPTIDASE U; CATTLE; CRYSTALLOGRAPHY, X-RAY; FIBRINOLYSIS; HEPARIN; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT; THERMODYNAMICS;

BOVINAE;

EID: 49449087930     PISSN: 10972765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molcel.2008.05.031     Document Type: Article

References (57)

1. Arimatsu Y. Latexin: a molecular marker for regional specification in the neocortex. Neurosci. Res. 20 (1994) 131-135
2. Arolas J.L., Lorenzo J., Rovira A., Castella J., Aviles F.X., and Sommerhoff C.P. A carboxypeptidase inhibitor from the tick Rhipicephalus bursa: isolation, cDNA cloning, recombinant expression, and characterization. J. Biol. Chem. 280 (2005) 3441-3448
3. Arolas J.L., Popowicz G.M., Lorenzo J., Sommerhoff C.P., Huber R., Avilés F.X., and Holak T.A. The three-dimensional structures of tick carboxypeptidase inhibitor in complex with A/B carboxypeptidases reveal a novel double-headed binding mode. J. Mol. Biol. 350 (2005) 489-498
4. Arolas J.L., Vendrell J., Avilés F.X., and Fricker L.D. Metallocarboxypeptidases: emerging drug targets in biomedicine. Curr. Pharm. Des. 13 (2007) 349-366
5. Auld D.S. 240. Carboxypeptidase A. In: Barrett A.J., Rawlings N.D., and Woessner Jr. J.F. (Eds). Handbook of proteolytic enzymes (2004), Elsevier Academic Press, London 812-821
6. Bajzar L., Manuel R., and Nesheim M.E. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 270 (1995) 14477-14484
7. Bedaiwy, M., and Casper, R. (2006). Diagnosis and treatment of endometriosis. In World Intellectual Property Organization (International Bureau, Mount Sinai Hospital, Toronto, CA), November 9, 2006. Patent no. WO 2006/116873A1.
8. Bjork I., and Lindahl U. Mechanism of the anticoagulant action of heparin. Mol. Cell. Biochem. 48 (1982) 161-182
9. Boffa M.B., Wang W., Bajzar L., and Nesheim M.E. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J. Biol. Chem. 273 (1998) 2127-2135
10. Boffa M.B., Bell R., Stevens W.K., and Nesheim M.E. Roles of thermal instability and proteolytic cleavage in regulation of activated thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 275 (2000) 12868-12878
11. Boffa M.B., Nesheim M.E., and Koschinsky M.L. Thrombin activable fibrinolysis inhibitor (TAFI): molecular genetics of an emerging potential risk factor for thrombotic disorders. Curr. Drug Targets Cardiovasc. Haematol. Disord. 1 (2001) 59-74
12. Boffa M.B., and Koschinsky M.L. Curiouser and curiouser: recent advances in measurement of thrombin-activatable fibrinolysis inhibitor (TAFI) and in understanding its molecular genetics, gene regulation, and biological roles. Clin. Biochem. 40 (2007) 431-442
13. Bouma B.N., and Mosnier L.O. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol. Haemost. Thromb. 33 (2003) 375-381
14. Buelens K., Hillmayer K., Compernolle G., Declerck P.J., and Gils A. Biochemical importance of glycosylation in thrombin activatable fibrinolysis inhibitor. Circ. Res. 102 (2008) 295-301
15. Carter W.J., Cama E., and Huntington J.A. Crystal structure of thrombin bound to heparin. J. Biol. Chem. 280 (2005) 2745-2749
16. CCP4 (Collaborative Computational Project, Number 4). The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50 (1994) 760-763
17. Ceresa E., Van de Borne K., Peeters M., Lijnen H.R., Declerck P.J., and Gils A. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant. J. Biol. Chem. 281 (2006) 15878-15883
18. Ceresa E., De Maeyer M., Jonckheer A., Peeters M., Engelborghs Y., Declerck P.J., and Gils A. Comparative evaluation of stable TAFIa variants importance of alpha-helix 9 and beta-sheet 11 for TAFIa (in)stability. J. Thromb. Haemost. 5 (2007) 2105-2112
19. Coll M., Guasch A., Aviles F.X., and Huber R. Three-dimensional structure of porcine procarboxypeptidase B: a structural basis of its inactivity. EMBO J. 10 (1991) 1-9
20. Do Y.H., Gifford-Moore D.S., Beight D.W., Rathnachalam R., Klimkowski V.J., Warshawsky A.M., and Lu D. Inhibition of thrombin activatable fibrinolysis inhibitor by cysteine derivatives. Thromb. Res. 116 (2005) 265-271
21. Eaton D.L., Malloy B.E., Tsai S.P., Henzel W., and Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J. Biol. Chem. 266 (1991) 21833-21838
22. Gabazza, E.C., Taguchi, O., Fujimoto, H., and Nagashima, M. (2006). TAFI inhibitors and their use to treat pulmonary fibrosis. In World Intellectual Property Organization (International Bureau, Schering AG, Berlin, Germany; Mie University Graduate School of Medicine, Mie, Japan; and Michael John Morser, San Francisco, CA, US), April 20, 2006. Patent no. WO 2006/041808 A2.
23. Hendriks D., Scharpé S., van Sande M., and Lommaert M.P. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J. Clin. Chem. Clin. Biochem. 27 (1989) 277-285
24. Hillmayer K., Macovei A., Pauwels D., Compernolle G., Declerck P.J., and Gils A. Characterization of rat thrombin-activatable fibrinolysis inhibitor (TAFI)-a comparative study assessing the biological equivalence of rat, murine and human TAFI. J. Thromb. Haemost. 4 (2006) 2470-2477
25. Hooper N.M. Families of zinc metalloproteases. FEBS Lett. 354 (1994) 1-6
26. Hsu, M.-Y., Matsueda, G.R., and Tamura, J.K. (2007). Baboon TAFI polypeptides. March 13, 2007. U.S. patent 7189829 (United States, Bristol-Myers Squibb Company).
27. Janin J., and Chothia C. The structure of protein-protein recognition sites. J. Biol. Chem. 265 (1990) 16027-16030
28. Klement P., Liao P., and Bajzar L. A novel approach to arterial thrombolysis. Blood 94 (1999) 2735-2743
29. Knecht W., Willemse J., Stenhamre H., Andersson M., Berntsson P., Furebring C., Harrysson A., Hager A.C., Wissing B.M., Hendriks D., and Cronet P. Limited mutagenesis increases the stability of human carboxypeptidase U (TAFIa) and demonstrates the importance of CPU stability over proCPU concentration in down-regulating fibrinolysis. FEBS J. 273 (2006) 778-792
30. Koradi R., Billeter M., and Wüthrich K. MOLMOL: A program for display and analysis of macromolecular structures. J. Mol. Graph. 14 (1996) 51-55
31. Mann K.G., Jenny R.J., and Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Annu. Rev. Biochem. 57 (1988) 915-956
32. Mao S.S., Cooper C.M., Wood T., Shafer J.A., and Gardell S.J. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. Modulation by glycosaminoglycans. J. Biol. Chem. 274 (1999) 35046-35052
33. Marx P.F., Hackeng T.M., Dawson P.E., Griffin J.H., Meijers J.C., and Bouma B.N. Inactivation of active thrombin-activable fibrinolysis inhibitor takes place by a process that involves conformational instability rather than proteolytic cleavage. J. Biol. Chem. 275 (2000) 12410-12415
34. Marx P.F., Havik S.R., Marquart J.A., Bouma B.N., and Meijers J.C. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor. J. Biol. Chem. 279 (2004) 6620-6628
35. Matsumoto A., Itoh K., and Matsumoto R. A novel carboxypeptidase B that processes native β-amyloid precursor protein is present in human hippocampus. Eur. J. Neurosci. 12 (2000) 227-238
36. Matsumoto A., Itoh K., Seki T., Motozaki K., and Matsuyama S. Human brain carboxypeptidase B, which cleaves β-amyloid peptides in vitro, is expressed in the endoplasmic reticulum of neurons. Eur. J. Neurosci. 13 (2001) 1653-1657
37. Mosnier L.O., and Bouma B.N. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2445-2453
38. Navaza J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 50 (1994) 157-163
39. Normant E., Martres M.P., Schwartz J.C., and Gros C. Purification, cDNA cloning, functional expression, and characterization of a 26-kDa endogenous mammalian carboxypeptidase inhibitor. Proc. Natl. Acad. Sci. USA 92 (1995) 12225-12229
40. Pallarès I., Bonet R., García-Castellanos R., Ventura S., Avilés F.X., Vendrell J., and Gomis-Rüth F.X. Structure of human carboxypeptidase A4 with its endogenous protein inhibitor, latexin. Proc. Natl. Acad. Sci. USA 102 (2005) 3978-3983
41. Pereira P.J.B., Segura-Martín S., Oliva B., Ferrer-Orta C., Avilés F.X., Coll M., Gomis-Rüth F.X., and Vendrell J. Human procarboxypeptidase B: three-dimensional structure and implications for thrombin-activatable fibrinolysis inhibitor (TAFI). J. Mol. Biol. 321 (2002) 537-547
42. Rees D.C., and Lipscomb W.N. Refined crystal structure of the potato inhibitor complex of carboxypeptidase A at 2.5 Å resolution. J. Mol. Biol. 160 (1982) 475-498
43. Refino C.J., de Guzman L., Schmitt D., Smyth R., Jeet S., Lipari M.T., Eaton D., and Bunting S. Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostasis. Fibrinol Proteol 14 (2000) 305-314
44. Reverter D., Fernandez-Catalan C., Baumgartner R., Pfander R., Huber R., Bode W., Vendrell J., Holak T.A., and Aviles F.X. Structure of a novel leech carboxypeptidase inhibitor determined free in solution and in complex with human carboxypeptidase A2. Nat. Struct. Biol. 7 (2000) 322-328
45. Schneider M., Boffa M., Stewart R., Rahman M., Koschinsky M., and Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J. Biol. Chem. 277 (2002) 1021-1030
46. Silveira A., Schatteman K., Goossens F., Moor E., Scharpe S., Stromqvist M., Hendriks D., and Hamsten A. Plasma procarboxypeptidase U in men with symptomatic coronary artery disease. Thromb. Haemost. 84 (2000) 364-368
47. Taylor, F.B., and Bajzar, L. (2005). Treatment of sepsis with TAFI. January 4, 2005. U.S. patent US6,838,432B2 (USA, Oklahoma Medical Research Foundation, Oklahoma City, OK, US; and McMaster University, Hamilton, CA).
48. Valnickova Z., Christensen T., Skottrup P., Thogersen I.B., Hojrup P., and Enghild J.J. Post-translational modifications of human thrombin-activatable fibrinolysis inhibitor (TAFI): evidence for a large shift in the isoelectric point and reduced solubility upon activation. Biochemistry 45 (2006) 1525-1535
49. Valnickova Z., Thogersen I.B., Potempa J., and Enghild J.J. Thrombin-activable fibrinolysis inhibitor (TAFI) zymogen is an active carboxypeptidase. J. Biol. Chem. 282 (2007) 3066-3076
50. Van Thiel D.H., George M., and Fareed J. Low levels of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with chronic liver disease. Thromb. Haemost. 85 (2001) 667-670
51. van Tilburg N.H., Rosendaal F.R., and Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 95 (2000) 2855-2859
52. Vendrell J., Querol E., and Avilés F.X. Metallocarboxypeptidases and their protein inhibitors. Structure, function and biomedical properties. Biochim. Biophys. Acta 1477 (2000) 284-298
53. Walsh P.N., Rizza C.R., Matthews J.M., Eipe J., Kernoff P.B., Coles M.D., Bloom A.L., Kaufman B.M., Beck P., Hanan C.M., and Biggs R. ε-Aminocaproic acid therapy for dental extractions in haemophilia and Christmas disease: a double blind controlled trial. Br. J. Haematol. 20 (1971) 463-475
54. Wang X., Smith P.L., Hsu M.Y., Tamasi J.A., Bird E., and Schumacher W.A. Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis. J. Thromb. Thrombolysis 23 (2007) 41-49
55. Willemse J.L., and Hendriks D.F. A role for procarboxypepidase U (TAFI) in thrombosis. Front. Biosci. 12 (2007) 1973-1987
56. 2-antiplasmin. Biochem. J. 191 (1980) 229-232
57. Zappacosta F., Pessi A., Bianchi E., Venturini S., Sollazzo M., Tramontano A., Marino G., and Pucci P. Probing the tertiary structure of proteins by limited proteolysis and mass spectrometry: the case of Minibody. Protein Sci. 5 (1996) 802-813